BioArctic AB Class B released its earnings results on Nov 13, 2025. The company reported -kr0.98 earnings per share for the quarter, beating the consensus estimate of -kr1.145 by kr0.165.

Is BioArctic AB Class B overvalued?

According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BioArctic AB Class B pay dividends?

BioArctic AB Class B pays a Notavailable dividend of kr1.5 which represents an annual dividend yield of N/A. See more information on BioArctic AB Class B dividends here

What is BioArctic AB Class B’s EPS estimate?

BioArctic AB Class B’s EPS estimate is -0.51.

How many shares outstanding does BioArctic AB Class B have?

BioArctic AB Class B has 74,237,490 shares outstanding.

What happened to BioArctic AB Class B’s price movement after its last earnings report?

BioArctic AB Class B reported an EPS of -kr0.98 in its last earnings report, beating expectations of -kr1.145. Following the earnings report the stock price went up 7.207%.

Which hedge fund is a major shareholder of BioArctic AB Class B?

Currently, no hedge funds are holding shares in SE:BIOA.B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BioArctic AB Class B

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.